Evidence map›Paper›PMID 42094613›Full record

ArticleTheranostics2026

Elevated target expression by dual PD-L1 and 4-1BB engagement is associated with

Claudia A J van Winkel, Xiaoyu Fan, Danique Giesen, Glenn Gauderat, Steven de Jong, Thomas Jaquin, Wim Timens, Agathe Lepissier, Marleen Richter, Stefan Grüner and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Claudia A J van WinkelDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen; Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
Xiaoyu FanDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen; Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
Danique GiesenDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen; Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
Glenn GauderatR&D Institute Servier Paris Saclay; 20 Route 128, 91190, Gif-sur-Yvette, France.
Steven de JongDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen; Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
Thomas JaquinPieris Pharmaceuticals; Zeppelinstraße 3, 85399, Hallbergmoos, Germany.
Wim TimensDepartment of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen; Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
Agathe LepissierR&D Institute Servier Paris Saclay; 20 Route 128, 91190, Gif-sur-Yvette, France.
Marleen RichterPieris Pharmaceuticals; Zeppelinstraße 3, 85399, Hallbergmoos, Germany.
Stefan GrünerPieris Pharmaceuticals; Zeppelinstraße 3, 85399, Hallbergmoos, Germany.
Nicole AndersenPieris Pharmaceuticals; Zeppelinstraße 3, 85399, Hallbergmoos, Germany.
Laurent LaboureurR&D Institute Servier Paris Saclay; 20 Route 128, 91190, Gif-sur-Yvette, France.
Lucia PattariniR&D Institute Servier Paris Saclay; 20 Route 128, 91190, Gif-sur-Yvette, France.
Helene LelièvreR&D Institute Servier Paris Saclay; 20 Route 128, 91190, Gif-sur-Yvette, France.
Elisabeth G E de VriesDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen; Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
Aizea Morales-KastresanaPieris Pharmaceuticals; Zeppelinstraße 3, 85399, Hallbergmoos, Germany.
Marjolijn N Lub-de HoogeDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen; Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The antibody-anticalin fusion protein (Mabcalin) targeting programmed cell death-ligand 1 (PD-L1) and T-cell costimulatory immunoreceptor CD137 (4-1BB) is designed to enhance T-cell reactivity while preventing T-cell inhibition by PD-L1/programmed cell death protein 1 (PD-1) checkpoint blockade. Using positron emission tomography (PET) imaging and

Indexed as

Antibodies, BispecificAntibodies, MonoclonalB7-H1 AntigenRadioisotopesTumor Necrosis Factor Receptor Superfamily, Member 9ZirconiumAnimalsCell Line, TumorFemaleHumansMicePositron-Emission TomographyTissue DistributionT-LymphocytesAntibodies, BispecificAntibodies, MonoclonalB7-H1 AntigenCD274 protein, humanRadioisotopesTumor Necrosis Factor Receptor Superfamily, Member 9ZirconiumZirconium-89biodistributionbispecific antibodiescancer immunotherapyPET imagingpharmacokinetics

Identifiers

PMID42094613
PMCPMC13142236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.